DOCSLIB.ORG

CT Differentiation of Ovarian Mucinous and Sero U S C Ys

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CT Differentiation of Ovarian Mucinous and Sero U S C Ys J Korean Radiol Soc 1999;4 :19 9-8 9 9 4 CT Differentiation of Ovarian Mucinous and Serou s Cys t a d e n o c a rc i n o m a 1 So n g - M ee Cho, M.D., Jae-Young Byun, M.D., Seung-Eun Jung, M.D.2, Bum-Soo Kim, M.D., Jae-Mun Lee, M.D.2, Joon-Mo Lee, M.D.3 Purpose : To assess the differences between imaging findings of mucinous and serous cystadenocarcinomas of the ovar y , as seen on computed tomography (CT). Materials and Methods : The CT findings of 24 patients with mucinous cystadenocar- cinoma (25 tumors) and 26 with serous cystadenocarcinoma (47 tumors) of the ovar y were retrospectively analysed. Images were evaluated for tumor size, contour, CT at- tenuation of locules within the mass, the presence of septal vegetation, the proportion of solid portion within the mass, the presence of calcification, and carcinomatosis peritonei. Results : Mucinous cystadenocarcinomas tend to have a smooth contour (96%), var i - able CT attenuation of locules (80 %), and even size of locules within the mass (88.0 %). Serous cystadenocarcinomas, on the other hand, tend to have an irregular lobulat- ed contour (89.4 %), unevenly sized locules (76.6%), septal vegetation (57.4 %), and a prominent solid portion (59.6%). Bilaterality and carcinomatosis peritonei were more common in serous than in mucinous cystadenocarcinoma. Conclusion : Features which are valuable for the differentiation of mucinous and serous cystadenocarcinomas of the ovar y , as seen on CT, are tumor size, contour, var y - ing locule attenuation and size, septal vegetation, a solid portion, bilaterality and peri- toneal seeding. Index words : Ova r y , neoplasms Ova r y , CT Epithelial cancers are the most common type of ovari- their clinical differentiation is not easy. In order to de- an malignancy, and may be serous (75 %), mucinous (20 termine the basis on which these two diseases may be %) or a mixture of other histologic types (5 %). In terms differentiated, we have therefore evaluated their respec- of their pathology, tumor behavior and prognosis, tive imaging features. serous and mucinous ovarian cancers are different, and Materials and Methods 1Department of Radiology, Kangnam St. Mary’s Hospital, College of Medicine, the Catholic University of Korea During a recent six-year period, CT images were ob- 2Department of Radiology, St. Mary’s Hospital, College of Medicine, the tained from 50 consecutive ovarian cystadenocarcino- Catholic University of Korea 3Department of Gynecology, Kangnam St. Mary’s Hospital, College of ma patients. Pathologic examination revealed 25 muci- Medicine, the Catholic University of Korea nous cystadenocarcinomas (one bilateral) in 24 patients Received June 2, 1999 ; Accepted August 2, 1999 Address reprint requests to : Jae Young Byun. M.D., Departments of aged 45 to 72 (mean, 59) years, and 47 serous cystadeno- Radiology, College of Medicine, The Catholic University of Korea. #505 Banpo-dong, Seocho-gu, Seoul 137-040, Korea. carcinomas (21 bilateral) in 26 patients aged 16 to 71 Tel. 82-2-590-1582 Fax. 82-2-599-6771 E-mail [email protected] (mean, 43) years. In all patients, CT images were ob- ─ 98 9 ─ Song-Mee Cho, et al : CT Differentiation of Ovarian Mucinous and Serous Cystadenocarcinoma tained one week before surgery, and retrospectively e- with a microlobulated contour was found. The propor- valuated. tion of solid portion of the mass was determined by the For CT, a Somatom Plus (Siemens, Erlangen, percentage of solid portion in relation to the entire mass, Germany), with 8-10 mm slice thickness and interval as seen on two dimensional images. The tumor was was used. Six hundred ml diluted diatrizoate meglu- considered mainly cystic when the solid portion com- mine (gastrografin 2%; Schering, Berlin, Germany) was prised 0-20 %, mixed solid and cystic when 20-50 % , orally administered 30-120 minutes before scanning. A and mainly solid when >50 %. Ascites, peritoneal nod- total of 100 ml iopromide 62.3% (Ultravist 300; Schering, ule and omental cake were considered indicative of car- Berlin, Germany) was injected as a bolus at a rate of 2- cinomatosis peritonei. 3 ml/sec using a mechanical injector. Incremental or spi- After comparing the CT imaging findings of mucinous ral scanning began 45 seconds after the start of intra- and serous cystadenocarcinomas, analyses using the venous injection of contrast media from the diaphragm to chi-square test, unpaired Student’s t test, and Mann- the symphysis. Whitney U test were performed. The chi-square test CT images were analyzed independently by two radi- was used to compare the two groups in terms of statisti- ologists without knowledge of the ultrasonographic or cally significant differences in tomor contour and CT at- pathologic results. The imaging features of ovarian ep- tenuation of locules, variation in the size of locules with- ithelial tumors were assessed with regard to tumor size, in the mass, the presence of septal vegetation, the pro- contour, difference in CT attenuation of locules within portion of solid portion within the mass, the presence of the mass, variation in the size of these locules, the pres- calcification, and the frequency of carcinomatosis peri- ence of septal vegetation, the proportion of solid compo- tonei. An unpaired Student’s t test was used to assess nent within the mass, the presence of calcification, bilat- the statistical significance of difference in tumor size be- erality and the frequency of carcinomatosis peritonei. tween the two groups. The Mann-Whitney U test was Tumor size was compared between two groups of ovari- used when one factor such as CA125 level was mea- an carcinomas by measuring the greatest diameter of sured on at least an ordinal scale. A p value of less than the masses. Tumor contour was defined as either s- 0.05 was considered staticstically significant. mooth or lobulated. Variations in the size of locules within the mass was subjectively defined as even or un- Re s u l t s even. Septal vegetation was considered to be present when lobulated endocystic or exocystic septal growth The clinical symptoms of patients with serous and A B Fig. 1. 71-year-old woman with left mucinous cystadenocarcinoma. A . Contrast enhanced pelvic CT shows a huge multiocular cystic mass with smooth contour, honeycombing appearance, and dif- ferent attenuation of locules. B. Lower level CT scan shows calcification (arrow) in the thickened septum (arrowheads). ─ 99 0 ─ J Korean Radiol Soc 1999;4 :19 9-8 9 9 4 mucinous cystadenocarcinomas were abdominal mass, noma patients (Fig. 4 ; p = .0001). Two cases of muci- bloating or mild abdominal pain. The differential imag- nous cystadenocarcinoma showed pseudomyxoma peri- ing features of serous and mucinous cystadenocarcino- to n e i . mas are summarized in Table 1. - The diameter of mucinous tumors was 8 27 (average, Di s c u s s i o n 15) cm and that of serous tumors was 3-18 (average, 8) cm (p<.001). Contour was smooth in 24 of 25 mucinous Common epithelial tumors of the ovary include cystadenocarcinomas (96 %) and lobulated in 42 of 47 serous, mucinous, endometrioid, clear cell, and other- serous cystadenocarcinomas (89.4 % ; p = .0001). CT at- tenuation of the locules varied in 20 of 25 mucinous tu- Table 1. CT Features of Mucinous and Serous Cystadenocarci- noma of the Ovary mors (Fig. 1), but in all but one serous cystadenocarcino- Cy s t a d e n o c a r c i n o m a ma (p=.0001). The size of locules within the mass was Fi n d i n g s even in 22 of 25 mucinous cystadenocarcinomas (88 % ; Mucinous (n=25) Serous (n=47) Fig 1), and uneven in 36 of 47 serous cystadenocarcino- Si z e 8-27 (mean,15) cm* 3-18 (mean, 8) cm* Lobulated contour 01 (4.0%) 42 (89.4%)* mas (76.6 % ; p = .0001). Septal vegetation was seen in Difference in cham. atten. 20 (80.0%)* 01 (2.2%) 27 serous cystadenocarcinomas (Fig. 2), but in only two Honeycombing appearance 22 (88.0%) 11 (23.4 %)* mucinous cystadenocarcinomas (p = .0001). Vegetation of septa 02 (8.0%) 27 (57.4%)* The proportion of intratumoral solid portion is sum- Ca l c i f i c a t i o n 05 (20.0%) 12 (25.5%) Bi l a t e r a l i t y 01 patient 21 patients* marized in Table 2. This was larger in cystadenocarcino- Carcinomatosis peritonei 00 patient 12 patients* mas (Fig. 2, 3) than in mucinous cystadenocarcinomas * p < 0.001 (p = .003). Calcifications within the tumor were seen in cham. : locule; atten. : CT attenuation 5 of 25 mucinous cystadenocarcinomas (20%) and 12 of 47 serous cystadenocarcinomas (25.5 %), with no statis- Table 2. Proportion of Solid Portion within the Mass in Mucin- tically significant difference between the two groups (p ous and Serous Cystadenocarcinoma = 0.773). Solid portion Mu c i n o u s Se r o u s Bilateral tumors were more common in the serous 00 - 20 % 20 (80.0%) 09 (19.1%) cystadenocarcinoma group than in the mucinous cys- 20 - 50 % 04 (16.0%) 10 (21.3%) tadenocarcinoma group (p = .0001). Carcinomatosis > 50 % 1 (4.0%) 028 (59.6%)* peritonei were found in only 12 serous cystadenocarci- * p<0.05 Fig. 2. 42-year-old woman with bilateral, mainly cystic masses Fig. 3. 72-year-old woman with bilateral serous cystadenocar- with large solid portions and vegetations (arrow) on postcon- cinoma. Contrast enhanced pelvic CT scan shows bilateral o- trast pelvic CT. Ehnancement of solid portion and intense en- varian masses, mainly solid on the left and solid and cystic on hancement of cystic and tumor wall can be visualized.
Load more

Recommended publications
  • Ovarian Cancer and Cervical Cancer
    What Every Woman Should Know About Gynecologic Cancer R. Kevin Reynolds, MD The George W. Morley Professor & Chief, Division of Gyn Oncology University of Michigan Ann Arbor, MI What is gynecologic cancer? Cancer is a disease where cells grow and spread without control. Gynecologic cancers begin in the female reproductive organs. The most common gynecologic cancers are endometrial cancer, ovarian cancer and cervical cancer. Less common gynecologic cancers involve vulva, Fallopian tube, uterine wall (sarcoma), vagina, and placenta (pregnancy tissue: molar pregnancy). Ovary Uterus Endometrium Cervix Vagina Vulva What causes endometrial cancer? Endometrial cancer is the most common gynecologic cancer: one out of every 40 women will develop endometrial cancer. It is caused by too much estrogen, a hormone normally present in women. The most common cause of the excess estrogen is being overweight: fat cells actually produce estrogen. Another cause of excess estrogen is medication such as tamoxifen (often prescribed for breast cancer treatment) or some forms of prescribed estrogen hormone therapy (unopposed estrogen). How is endometrial cancer detected? Almost all endometrial cancer is detected when a woman notices vaginal bleeding after her menopause or irregular bleeding before her menopause. If bleeding occurs, a woman should contact her doctor so that appropriate testing can be performed. This usually includes an endometrial biopsy, a brief, slightly crampy test, performed in the office. Fortunately, most endometrial cancers are detected before spread to other parts of the body occurs Is endometrial cancer treatable? Yes! Most women with endometrial cancer will undergo surgery including hysterectomy (removal of the uterus) in addition to removal of ovaries and lymph nodes.
    [Show full text]
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • "General Pathology"
    ,, ., 1312.. CALIFORNIA TUMOR TISSUE REGISTRY "GENERAL PATHOLOGY" Study Cases, Subscription B October 1998 California Tumor Tissue Registry c/o: Department of l'nthology and Ruman Anatomy Loma Lindn Universily School'oflV.lcdicine 11021 Campus Avenue, AH 335 Lomn Linda, California 92350 (909) 824-4788 FAX: (909) 478-4188 E-mail: cU [email protected] CONTRIBUTOR: Philip G. R obinson, M.D. CASE NO. 1 - OcrOBER 1998 Boynton Beach, FL TISSUE FROM: Stomach ACCESSION #28434 CLINICAL ABSTRACT: This 67-year-old female was thought to have a pancreatic mass, but at surgery was found to have a nodule within the gastric wall. GROSS PATHOLOGY: The specimen consisted of a 5.0 x 5.5 x 4.5 em fragment of gray tissue. The cut surface was pale tan, coarsely lobular with cystic degeneration. SPECIAL STUDIES: Keratin negative Desmin negative Actin negative S-100 negative CD-34 trace to 1+ positive in stromal cells (background vasculature positive throughout) CONTRIBUTOR: Mar k J anssen, M.D. CASE NO. 2 - ocrOBER 1998 Anaheim, CA TISSUE FROM: Bladder ACCESSION #28350 CLINICAL ABSTRACT: This 54-year-old male was found to have a large rumor in his bladder. GROSS PATHOLOGY: The specimen consisted of a TUR of urinary bladder tissue, forming a 7.5 x 7. 5 x 1.5 em aggregate. SPECIAL STUDfES: C)1okeratin focally positive Vimentin highly positive MSA,Desmin faint positivity CONTRIBUTOR: Howard Otto, M.D. CASE NO.3 - OCTOBER 1998 Cheboygan, Ml TISSUE FROM: Appendix ACCESSION #28447 CLINICAL ABSTRACT: This 73-year-old female presented with acute appendicitis and at surgery was felt to have a periappendiceal abscess.
    [Show full text]
  • Pure Choriocarcinoma of the Ovary: a Case Report
    Case Report J Gynecol Oncol Vol. 22, No. 2:135-139 pISSN 2005-0380 DOI:10.3802/jgo.2011.22.2.135 eISSN 2005-0399 Pure choriocarcinoma of the ovary: a case report Lin Lv1, Kaixuan Yang2, Hai Wu1, Jiangyan Lou1, Zhilan Peng1 Departments of 1Obstetrics and Gynecology and 2Pathology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China Pure ovarian choriocarcinomas are extremely rare and aggressive tumors which are gestational or non­gestational in origin. Due to the rarity of the tumor, there is a lack of information on the clinicopathologic features, diagnosis, and treatment. We report a case of a pure ovarian choriocarcinoma, likely of non­gestational origin, treated by cytoreductive surgery in combination with post­operative chemotherapy. The patient was free of disease after a 12­month follow­up. Keywords: Choriocarcinoma, Non­gestational, Ovary INTRODUCTION CASE REPORT Pure ovarian choriocarcinomas are extremely rare malignan­ A 48­year­old woman was admitted to our department cies which are of gestational or non­gestational in origin. with a 6­month history of irregular vaginal bleeding and a The gestational type may arise from an ectopic ovarian pre­ 1­month history of a palpable abdominal mass. She had a gnancy or present as a metastasis from a uterine or tubal nor mal vaginal delivery at 26 years of age and had no recent choriocarcinoma, while the non­gestational type is a rare history of normal pregnancies, molar gestations, or abortions. germ cell tumor with trophoblastic differentiation. The esti­ The physical examination revealed abdominal tenderness and mated incidence of gestational ovarian choriocarcinomas a fixed mass arising from the pelvis to 3 cm below the um­ is 1 in 369 million pregnancies [1].
    [Show full text]
  • CASOLA Pancreas
    PANCREAS • Acute pancreatitis • Pancreatic Tumors Acute Pancreatitis Acute Pancreatitis Clinical Spectrum The most terrible of all calamities Mild Severe that occur in connection with the abdominal viscera. interstitial necrotizing edematous fulminant Moynihan B. Ann Surg. 1925;81:132-142 self-limiting lethal Acute Pancreatitis Pathophysiology Mild Acute Pancreatitis Activation of Pancreatic Enzymes Netter Ciba Collection Mediators, cytokines release Systemic manifestations SIRS MODS ARDS SEPSIS Severe Acute Pancreatitis Predictors of Severity • Clinical scores: Ranson, Apache II • Biologic Markers: CRP, IL Netter Ciba Collection • Contrast enhanced CT Acute Pancreatitis Radiologic Imaging Patients Peak • CT: modality of choice present to cytokine End organ hospital production dysfunction • US: assess biliary tree, F/U PC, Doppler • MRI: MRCP • ERCP: therapeutic stone removal 12 -18 30 48 - 96 Hours CECT • Angio/IR: complications Biological Ranson Markers Apache II Segmental Acute Pancreatitis Focal Pancreatitis CT Staging Systems Pancreatic Necrosis Balthazar Classification • 20 - 30 % of cases • Pancreatic Necrosis • Early presentation < 96 hours • CT Grade: A - E Grade E • Focal or diffuse • Decreased enhancement on CT • CT severity index • CT accuracy 80 - 90% • Increased risk of MOF Pancreatic Necrosis Pancreatic Necrosis < 30% 30-50% Disconnected Pancreatic Duct Pancreatic Necrosis Syndrome >50% • Viable pancreatic tail is isolated and unable to drain into duodenum • 30% cases necrotizing pancreatitis • Usually occurs at the neck
    [Show full text]
  • Combined Goblet Cellcarcinoid and Mucinous Cystadenoma of The
    I Clin Pathol 1995;48:869-870 869 Combined goblet cell carcinoid and mucinous cystadenoma of the appendix J Clin Pathol: first published as 10.1136/jcp.48.9.869 on 1 September 1995. Downloaded from R K Al-Talib, C H Mason, J M Theaker Abstract Case reports Two cases of combined goblet cell car- CASE ONE cinoid and mucinous cystadenoma oc- An adherent pelvic appendix was resected with curring in the appendix are reported. The difficulty from a 54 year old woman admitted histogenesis of the goblet cell carcinoid for an interval appendicectomy, two months remains one of its most controversial as- after an attack of appendicitis. The appendix pects and the occurrence of both of these measured 60 x 15 mm and was irregular, dis- relatively uncommon tumours in the same torted and showed serosal fibrosis. On sec- organ may lend support to the unitary tioning, the tip of the appendix was distended stem cell hypothesis on the origin of this and a mucus containing diverticulum pen- tumour. Alternatively, this occurrence etrating the muscular wall of the appendix was may represent an example ofthe adenoma/ identified. carcinoma sequence. ( Clin Pathol 1995;48:869-870) Department of CASE TWO Histopathology, Keywords: Goblet cell carcinoid, mucinous cyst- A 64 year old woman was a Southampton adenoma, appendix, histogenesis. admitted with four University Hospitals month history of a dull ache in the right iliac NHS Trust, fossa which had become increasingly severe Southampton S09 4XY R K Al-Talib Goblet cell carcinoid is an uncommon tumour over the last week.
    [Show full text]
  • Differential Diagnosis of Ovarian Mucinous Tumours Sigurd F
    Differential Diagnosis of Ovarian Mucinous Tumours Sigurd F. Lax LKH Graz II Academic Teaching Hospital of the Medical University Graz Pathology Mucinous tumours of the ovary • Primary ➢Seromucinous tumours ➢Mucinous tumours ➢Benign, borderline, malignant • Secondary (metastatic) ➢Metastases (from gastrointestinal tract) • Metastases can mimic primary ovarian tumour Mucinous tumours: General • 2nd largest group after serous tumours • Gastro-intestinal differentiation (goblet cells) • Endocervical type> seromucinous tumours • Majority is unilateral, particularly cystadenomas and borderline tumours • Bilaterality: rule out metastatic origin • Adenoma>carcinoma sequence reflected by a mixture of benign, atypical proliferating and malignant areas within the same tumour Sero-mucinous ovarian tumours • Previous endocervical type of mucinous tumor • Mixture of at least 2 cell types: mostly serous • Association with endometriosis; multifocality • Similarity with endometrioid and serous tumours, also immunophenotype • CK7, ER, WT1 positive; CK20, cdx2 negativ • Most cystadenoma and borderline tumours • Carcinomas rare and difficult to diagnose Shappel et al., 2002; Dube et al., 2005; Vang et al. 2006 Seromucinous Borderline Tumour ER WT1 Seromucinous carcinoma being discontinued? • Poor reproducibility: Low to modest agreement from 39% to 56% for 4 observers • Immunophenotype not unique, overlapped predominantly with endometrioid and to a lesser extent with mucinous and low-grade serous carcinoma • Molecular features overlap mostly with endometrioid
    [Show full text]
  • Photodynamic Therapy for Gynecological Diseases and Breast Cancer
    CancCancerer Biol Med 2012;2012 /9: Vol. 9-17 9 /doi: No. 10.3969/j.issn.2095-3941.2012.1 01.002 9 Review Photodynamic Therapy for Gynecological Diseases and Breast Cancer Natashis Shishkova, Olga Kuznetsova, Temirbolat Berezov Department of Biochemistry, School of Medicine, People’s Friendship University of Russia, Moscow 117198, Russia ABSTRACT Photodynamic therapy (PDT) is a minimally invasive and promising new method in cancer treatment. Cytotoxic reactive oxygen species (ROS) are generated by the tissue-localized non-toxic sensitizer upon illumination and in the presence of oxygen. Thus, selective destruction of a targeted tumor may be achieved. Compared with traditional cancer treatment, PDI has advantages including higher selectivity and lower rate of toxicity. The high degree of selectivity of the proposed method was applied to cancer diagnosis using fluorescence. This article reviews previous studies done on PDT treatment and photodetection of cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, ovarian and breast cancer, and PDT application in treating non-cancer lesions. The article also highlights the clinical responses to PDT, and discusses the possibility of enhancing treatment efficacy by combination with immunotherapy and targeted therapy. KEY WORDS: photodynamic therapy, photosensitizers, cervical/vulvar intraepithelial neoplasia, ovarian neoplasms, breast neoplasms Introduction frequently used drug in PDT is 5-aminolaevulinic acid (ALA). However, 5-ALA is not a photosensitizer, but a precursor of Photodynamic therapy (PDT) is a mode of therapy used in the endogenous photosensitizer protoporphyrin IX, which is cancer treatment where drug activity is locally controlled by a member of the heme synthesis pathway that occurs in the light (Figure 1).
    [Show full text]
  • What Is New on Ovarian Carcinoma
    diagnostics Review What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors Antonio De Leo 1,2,3,*,† , Donatella Santini 3,4,† , Claudio Ceccarelli 1,3, Giacomo Santandrea 5 , Andrea Palicelli 5 , Giorgia Acquaviva 1,2, Federico Chiarucci 1,2 , Francesca Rosini 4, Gloria Ravegnini 3,6 , Annalisa Pession 2,6, Daniela Turchetti 3,7, Claudio Zamagni 8, Anna Myriam Perrone 3,9 , Pierandrea De Iaco 3,9, Giovanni Tallini 1,2,3,‡ and Dario de Biase 2,3,6,‡ 1 Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum—University of Bologna, Via Massarenti 9, 40138 Bologna, Italy; [email protected] (C.C.); [email protected] (G.A.); [email protected] (F.C.); [email protected] (G.T.) 2 Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero—Universitaria di Bologna/Azienda USL di Bologna, 40138 Bologna, Italy; [email protected] (A.P.); [email protected] (D.d.B.) 3 Centro di Studio e Ricerca delle Neoplasie Ginecologiche, Alma Mater Studiorum—University of Bologna, 40138 Bologna, Italy; [email protected] (D.S.); [email protected] (G.R.); [email protected] (D.T.); [email protected] (A.M.P.); [email protected] (P.D.I.) 4 Pathology Unit, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy; [email protected] 5 Citation: De Leo, A.; Santini, D.; Pathology Unit, AUSL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy; Ceccarelli, C.; Santandrea, G.; [email protected] (G.S.); [email protected] (A.P.) 6 Palicelli, A.; Acquaviva, G.; Chiarucci, Department of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy 7 Unit of Medical Genetics, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Via Massarenti 9, F.; Rosini, F.; Ravegnini, G.; Pession, 40138 Bologna, Italy A.; et al.
    [Show full text]
  • Malignant Transformation of Liver Cysts Into Cholangiocarcinoma During Follow-Up: Potential Dangers of Liver Cysts
    Malignant Transformation of Liver Cysts Into Cholangiocarcinoma During Follow-up: Potential Dangers of Liver Cysts Fu-sheng Liu Wuhan University Second Clinical Hospital: Wuhan University Zhongnan Hospital https://orcid.org/0000-0003-1175-5209 Ke-lu Li Department of Pathology, Wuhan University Zhongnan Hospital Yue-ming He Department of Hepatobiliary&Pancreatic Surgery, Zhongnan Hospital of Wuhan University Zhong-lin Zhang Department of Hepatobiliary&Pancreatic Surgery, Zhongnan Hospital of Wuhan University Yu-feng Yuan Department of Hepatobiliary&Pancreatic Surgery, Zhongnan Hospital of Wuhan University Hai-tao Wang ( [email protected] ) Wuhan University Second Clinical Hospital: Wuhan University Zhongnan Hospital Case Report Keywords: Liver cysts, intrahepatic cholangiocarcinoma, malignant transformation Posted Date: July 9th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-684869/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/12 Abstract Background: The liver cyst is a common disease in hepatobiliary surgery. Most patients have no apparent symptoms and are usually diagnosed accidentally during imaging examinations. The vast majority of patients with liver cysts follow a benign course, with very few serious complications and rare reports of malignant changes. Case Presentation: We present two cases of liver cysts that evolved into intrahepatic tumors during the follow-up process. The rst patient had undergone a fenestration and drainage operation for the liver cyst, and the cancer was found at the cyst’s position in the third year after the procedure. Microscopically, bile duct cells formed the cyst wall. Tumor cells can be seen on the cyst wall and its surroundings to form adenoid structures of different sizes, shapes, and irregular arrangements, some of which are arranged in clusters.
    [Show full text]
  • Germline Fumarate Hydratase Mutations in Patients with Ovarian Mucinous Cystadenoma
    European Journal of Human Genetics (2006) 14, 880–883 & 2006 Nature Publishing Group All rights reserved 1018-4813/06 $30.00 www.nature.com/ejhg SHORT REPORT Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma Sanna K Ylisaukko-oja1, Cezary Cybulski2, Rainer Lehtonen1, Maija Kiuru1, Joanna Matyjasik2, Anna Szyman˜ska2, Jolanta Szyman˜ska-Pasternak2, Lars Dyrskjot3, Ralf Butzow4, Torben F Orntoft3, Virpi Launonen1, Jan Lubin˜ski2 and Lauri A Aaltonen*,1 1Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland; 2International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; 3Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark; 4Pathology and Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland Germline mutations in the fumarate hydratase (FH) gene were recently shown to predispose to the dominantly inherited syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma. The aim of this study was to identify new families with FH mutations, and to further examine the tumor spectrum associated with FH mutations. FH germline mutations were screened from 89 patients with RCC, skin leiomyomas or ovarian tumors. Subsequently, 13 ovarian and 48 bladder carcinomas were analyzed for somatic FH mutations. Two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers. One of the changes was a novel mutation (Ala231Thr) and the other one (435insAAA) was previously described in FH deficiency families. These results suggest that benign ovarian tumors may be associated with HLRCC.
    [Show full text]
  • Focal Pancreatic Lesions: Role of Contrast-Enhanced Ultrasonography
    diagnostics Review Focal Pancreatic Lesions: Role of Contrast-Enhanced Ultrasonography Tommaso Vincenzo Bartolotta 1,2 , Angelo Randazzo 1 , Eleonora Bruno 1, Pierpaolo Alongi 2,3,* and Adele Taibbi 1 1 BiND Department: Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Del Vespro, 129, 90127 Palermo, Italy; [email protected] (T.V.B.); [email protected] (A.R.); [email protected] (E.B.); [email protected] (A.T.) 2 Department of Radiology, Fondazione Istituto Giuseppe Giglio Ct.da Pietrapollastra, Via Pisciotto, Cefalù, 90015 Palermo, Italy 3 Unit of Nuclear Medicine, Fondazione Istituto Giuseppe Giglio Ct.da Pietrapollastra, Via Pisciotto, Cefalù, 90015 Palermo, Italy * Correspondence: [email protected] Abstract: The introduction of contrast-enhanced ultrasonography (CEUS) has led to a significant improvement in the diagnostic accuracy of ultrasound in the characterization of a pancreatic mass. CEUS, by using a blood pool contrast agent, can provide dynamic information concerning macro- and micro-circulation of focal lesions and of normal parenchyma, without the use of ionizing radiation. On the basis of personal experience and literature data, the purpose of this article is to describe and discuss CEUS imaging findings of the main solid and cystic pancreatic lesions with varying prevalence. Keywords: contrast-enhanced ultrasound; pancreas; diagnostic imaging Citation: Bartolotta, T.V.; Randazzo, A.; Bruno, E.; Alongi, P.; Taibbi, A. Focal Pancreatic Lesions: Role of Contrast-Enhanced Ultrasonography. 1. Introduction Diagnostics 2021, 11, 957. Contrast-enhanced Ultrasound (CEUS) allows non-invasive assessment of normal and https://doi.org/10.3390/ pathologic perfusion of various organs in real time throughout the vascular phase, without diagnostics11060957 the use of ionizing radiation and with a much higher temporal resolution than Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) [??? ].
    [Show full text]